The women’s health market is predicted to be among the fastest growing investment areas within the healthcare and life sciences industry. Life sciences companies and healthcare providers, as well as the governmental bodies that regulate them, are abandoning a “one-size-fits-all” approach to treatment in favor of approaches more tailored to specific groups, including women. King & Spalding’s Women’s Health team has decades of experience advising companies in this space on issues that arise throughout the lifecycle of medical products – including intellectual property issues, corporate and M&A issues, FDA-related issues, issues related to product coverage and reimbursement, healthcare provider issues, and product liability issues. Clients include drug and device manufacturers, health care providers, private equity firms, and others.
Back to Focus on Women's Health
March 14, 2022
Health Headlines– March 14, 2022
February 7, 2022
A Pandemic Silver Lining: FDA’s New Guidance on Using Digital Health Technologies for Clinical Investigations
January 26, 2022
Spotlight on PFAS and Other Substances in Cosmetics Likely to Grow in 2022
November 9, 2022
Val Leppert and Heather Howard counsel Coloplast before the Eleventh Circuit, which refused to revive claims against the company in a pelvic mesh dispute
July 19, 2022
Aaron Parks obtains a successful summary judgment motion on behalf of Coloplast before a Minnesota federal court
March 1, 2022
Melvin Bailey Inducted Into American College of Trial Lawyers
King & Spalding Advised the Founder, CEO and Majority Owner of Vogue International in Its $3.3 Billion Sale to Johnson & Johnson Consumer Inc.
Lana Varney, Julia Zousmer, Heather Howard to Speak at Defense Research Institute’s Annual Drug & Medical Device Seminar